ANDA 203778, held by 3d Imaging Drug. Fludeoxyglucose F-18.
As of Nov 16, 2026, ANDA 203778 (Fludeoxyglucose F18), held by 3d Imaging Drug, was first approved by FDA on Oct 30, 2015, with 1 approved supplement and 0 published complete response letters.
Fludeoxyglucose F18 Injection is indicated for positron emission tomography (PET) imaging in the following settings:
| Date | Submission | Status | Documents |
|---|---|---|---|
| Oct 30, 2015 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Fludeoxyglucose F1820-300mCi/ML · injectable;intravenous | Fludeoxyglucose F-18 | Rx |
| Jun 24, 2020 | Supplement 2Manufacturing | Approved | None posted |
| Oct 30, 2015 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters